Intraspinal morphine for cancer pain

Area of Science:

• Pain Management
• Oncology
• Pharmacology

Background:

• Chronic cancer pain management remains challenging.
• Intraspinal morphine administration is an option for refractory cancer pain.
• Limited data exist on long-term efficacy and complications of intraspinal morphine.

Purpose of the Study:

• To review the literature on chronic intraspinal morphine for cancer pain.
• To evaluate the efficacy and safety of epidural and intrathecal morphine administration.
• To identify limitations and challenges in intraspinal morphine therapy.

Main Methods:

• Literature review of 412 cases of intraspinal morphine for cancer pain.
• Clinical experience with 22 patients receiving epidural morphine.
• Clinical experience with 53 patients receiving intrathecal morphine.

Main Results:

• Lack of comprehensive follow-up data on pain relief and complications in existing literature.
• Continuous administration via closed systems demonstrates superior long-term pain relief efficacy.
• Tolerance is a significant factor in prolonged intraspinal morphine administration.
• Epidural administration is associated with fewer serious side-effects compared to intrathecal.
• Certain pain types are refractory to morphine, even with intraspinal administration.

Conclusions:

• Continuous intraspinal morphine, particularly via closed systems, is effective for long-term cancer pain management.
• Tolerance and non-responsive pain types necessitate ongoing research and alternative strategies.
• Epidural administration appears safer than intrathecal, but technical complications can limit use.
• Further research is needed to address data gaps in follow-up and complications.